PolarityTE Inc.

PolarityTE — Investor Presentation (July 2021)

33 slides from PolarityTE's investor presentation, Jul 28, 2021

  1. Slide 1: PolarityTE Investor Presentation July 2021

    Polarit tyIE Investor Presentation Where Self Regenerates Self” Jul y 2021

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement Brive This presentation contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties and investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Forward-lookin

  3. Slide 3: Our Mission: Transforming the lives of patients

    Our Mission: Transforming the lives of patients... By unlocki e potential of autologous therapy —Devon, Chronic Wound —Diane, Skin Cancer Survivor and —Natasha, Burn Survivor and SkinTE Patient SkinTE Patient SkinTE Patient © 2021 PolarityTE, Inc. All Rights Reserved. For Investors Only. Not For Gen

  4. Slide 4: Challenges in Wound Care

    Challenges in Wound Care Brive Problem ~8.2m Medicare beneficiaries had wounds with or without infection in 2018! Market Medicare cost estimates for acute and chronic wound treatments ranged from $28.1 billion to $96.8 billion! Existin Common treatments such as split-thickness skin grafting have ‘in

  5. Slide 5: PolarityTE Highlights

    PolarityTE Highlights PolarityTE” Where Set Regenettes Sef >1,200 Clinical Cases Focused on Unmet Medical Need: Real-World Tested in Challenging Wounds Compelling Data: Robust, Reproduceable and Differentiated Data Including Randomized Controlled Trials Focused Pipeline: skinTE Point of Care, SkinTE

  6. Slide 6: Gaining Value Through the BLA

    Gaining Value Through the BLA Brive BLA Value Proposition = BLA requires robust data to establish safety and efficacy > Clinical evidence should enhance adoption and support reimbursement post approval = FDA approval process > Defined indications for use should support enhanced provider adoption and

  7. Slide 7: SkinTE Positioned to Expand Access and Care

    SkinTE Positioned to @ Expand Access and Care SkinTE Chronic Cutaneous Wounds: + Diabetic Foot Ulcers + Pressure Injuries & Wound Care Clinics + Venous Leg Ulcers Physicians: Physician Offices Traumatic Injuries + Surgical Inpatient Bedside and ICU Barns (Aaite ona « Non-Surgical Inpatient Operating

  8. Slide 8: Leveraging Pre-BLA Commercial Experience

    Leveraging Pre-BLA Commercial Experience Brive hee Seeger — _ = = ann in re-users (Q1:20- Denloved( Optinued product oeay Evidence to be difficult-to-treat outcomes Complex traumatic 5 quarters of growth fl eaded wounds (exposed in revenue (Q1:20- vera i uring wounds Discovered new structures) eal S

  9. Slide 9: Our SkinTE Technology: A Novel and Differentiated Approach

    Our SkinTE Technology: A Novel and Differentiated Approach Technological Characteristics Autologous Personalized product that utilizes the patient's Tissue own viable tissue and cells Autologous multicellular segments include cellular populations found within the epidermis and dermis Regeneration Po

  10. Slide 10: Complex Tissue Regeneration — From the Bench to the Bedside

    Complex Tissue Regeneration — From the Bench to the Bedside Development of in-house animal* wound models and tissue analysis to unlock regenerative potential a as Understanding skin's complex regenerative cellular biology (B) Full-thickness human skin and human hair follicle regeneration within a mo

  11. Slide 11: Complex Tissue Regeneration — From the Bench to the Bedside (Continued)

    Complex Tissue Regeneration — a From the Bench to the Bedside (Continued) Rapid translation of bench research to patient bedside to optimize SkinTE for full-thickness skin regeneration in complex wounds Harnessing skin's regenerative potential (A) SkinTE retains endogenous stem cell associated gene

  12. Slide 12: SkinTE Process Logistics

    SkinTE Process Logistics Brive Anticipated based on prior clinical experience inTE Harvest Box Ful jickness Skin Harvested

  13. Slide 13: SkinTE — A Different Approach and Unique Product Characteristics

    SkinTE — A Different Approach and = Unique Product Characteristics Unique nature of clinical attributes with SkinTE has the potential to create a new approach for acute and chronic full-thickness wounds + Autologous * Typically, single application + Volume filling of deep wounds * Tissue coverage of

  14. Slide 14: Peer Reviewed Publications

    Peer Reviewed Publications 10. a 2 © 2021 PolarityTE, Inc. All “Amulticentre, randomised controlled clinical tral evaluating the effects of a novel autologous, heterogeneous skin construct in the treatment of Wagner one iabetic foot ulcers: Interim analysis" in International Wound Journal “Autologou

  15. Slide 15: Product Portfolio and Pipeline

    Product Portfolio and Pipeline Brive Development Status Indication / Application Proof of Concept _Pre-IND Submission IND Acceptance Trial Enrolling SkinTE used in over 1,200 clinical cases under the 361 HCT/P Pathway Chronic Cutaneous Wounds: Diabetic Foot Ulcers, Venous Leg IND Submitted Trial enr

  16. Slide 16: SkinTE for Diabetic Foot Ulcers Represents a Significant Commercial Opportunity

    SkinTE for Diabetic Foot Ulcers Represents ® a Significant Commercial Opportunity 34m Lifetime incidence of diabetes expected to Diabetics in the United States? ganinuete ieresein both the US and globally’ 2.2m DFU Annual Incidence Rate* DFUs expected to 1 4m increase in Unhealed DFUs parallel® foll

  17. Slide 17: Diabetic Foot Ulcers: Patient Impact

    Diabetic Foot Ulcers: Patient Impact Brive "Five-year mortality and direct costs of care for people with diabetic foot ulcer complications are comparable to cancer” - Armstrong et al’ 1/3 Of Diabetic Patients with a DFU will have an amputation’? 56.6% 5 Year mortality of major amputation secondary t

  18. Slide 18: SkinTE for Diabetic Foot Ulcers

    SkinTE for Diabetic Foot Ulcers Brive DFU Outcomes from Pilot Trial? ~ ; Success in closing DFUs » ; ~ in randomized controlled trial m and real-world evidence? Initial wound ~9 weeks after single Initial wound ~B weeks after application of SkinTE single application of SkinTE SkinTE in Full-Thicknes

  19. Slide 19: DFU Randomized Controlled Trial Design

    DFU Randomized Controlled Trial Design Brive Prospective, multi-center, randomized controlled trial evaluating SkinTE (AHSC) plus standard of care (SOC) vs. SOC alone in the treatment of DFUs Patient Signs Inclusion Criteria: Informed Consent * Wagner 1 DFU below the medial malleolus + Index ulcer 2

  20. Slide 20: DFU Randomized Controlled Trial Design

    DFU Randomized Controlled Trial Design Brive 100 patients: 50 AHSC + SOC, 50 SOC were enrolled across 13 sites End of Study Visit ‘Closure Confirmation Visit at 2 Weeks Ulcer Closed or Received 12 Weekly Visits? Not Closed Subject Continues stud atl End of Study Visit D 2021 PolarityTE, Inc. Primary

  21. Slide 21: Valuable Outcomes for Patients, Providers & Payers

    Valuable Outcomes for =) Patients, Providers & Payers fa Application BA of AHSC Primary Endpoint Secondary Endpoint Number of Applications Closure at 12 Weeks Increased Percent Area Reduction Applications of SkinTE (PAR) at 4, 6, 8, 10 and 12 Weeks AHSC: 35/50 (70%) Closed 1 Application: 45/50 (90%)

  22. Slide 22: SkinTE for Pressure Injury Represents a Significant Commercial Opportunity

    SkinTE for Pressure Injury Represents ® a Significant Commercial Opportunity 2.5m Hospital acquired pressure injuries (HAPIs) are the most common of Acute Care Patients!” hospital acquired jospital acquired ~1Im condition (HAC)'5 conditions unts for 45% of Affected Patient in the US per year"® s sec

  23. Slide 23: Pressure Injury Patient and Cost Burden

    Pressure Injury Patient and Cost Burden Brive Stage III/IV pressure injuries account for 73% of all recurrence and 59% of the total PI cost to the system02" $26.8B Estimated annual cost of HAPI to the system?! Average length of stay for patients with PI vs 5 days for all other conditions?? $43,180 T

  24. Slide 24: SkinTE for Pressure Injury

    SkinTE for Pressure Injury Brive hr eos Real world evidence supports Residual Limb Pressure Injury” proof of concept in pressure injury2425 Only 50% of stage Ill ulcers and e 30% of stage IV ulcers heal Ital wound TI wee afer single 23 weeks afer dng mien : apaiceson ofSoniE —oppicadon of Sor within

  25. Slide 25: SkinTE for Acute Trauma

    SkinTE for Acute Trauma Brive SkinTE has been successfully deployed in clinical use for acute ~84K Trauma cases per year?® traumatic wounds This patient cohort is admitted to the hospital with open ; wounds as a primary diagnosis Ideal patient population for a single application product Using tibial

  26. Slide 26: SkinTE for Burns

    SkinTE for Burns @ reese hee Sefer Acute Burn Opportunity Advantageous Positio: SkinTE has demonstrated a ~42K Burn Cases Per Mice favorable donor site to wound size applicable for SkinTE ratio which is critical in burn?¢ ~20% of these patients are recording Total Burn Surface areas (TBSA) of 10% or

  27. Slide 27: De-Risked Asset Driving Near and Long-Term Growth

    De-Risked Asset Driving @® Near and Long-Term Growth Real World Experience @ 1,200 SkinTE applications Scientific Body of Evidence g DFU multi-center randomized trial of 100 patients met primary and secondary endpoint g > 10 peer-reviewed SkinTE scientific publication Intellectual Property (o) Total

  28. Slide 28: Cash and Cash Equivalents: ~$37.2 million as of March 31, 2021

    Fe Cash and Cash Equivalents: ~$37.2 million as of March 31, 2021 Market Cap: $63.27 million as of July 26, 2021 Shares Outstanding: 81,064,080 as of July 26, 2021 Warrants Outstandin 314,143 as of March 31, 2021 ATM: up to $50.0 million as of March 30, 2021 Focused on Capital Efficiency i) © 2021 P

  29. Slide 29: Management

    Management Brive Executive Management Team David Seaburg Richard Hague Jacob Patterson «al y Ryan Mathis, MD Vice President of ‘Commercial Strategy DDS, DSc, FACS Chief Clinical Officer Chief Scientitic Officer & Vice President R&D Stephen Milner, MD, Nikolai Sopko, MD, PhD 35 Cameron Hoyler, JD Exe

  30. Slide 30: Board of Directors

    Board of Directors Brive Peter Cohen, MBA Minnie Baylor-Henry, JD Willie Bogan, JD, MA Garnensithe toad Direcior Diettor gibt non am "ome in nee ey atte ee Cae in fame Chand Dot Cowen be acre el ‘ooaanrsndbancaes Eero pe sn yn Chris Nolet Jeff Dyer, MBA, PhD Jessica Shen, MD Director & Chairman of t

  31. Slide 31: Appendix

    Polarit tyIE" Appendix Where SelfRegenerates Self”

  32. Slide 32: References

    References @ reese hee Sefer 19. Sen, Chandan K. “Human Wounds and Its Burden: An Updated Compencium of Estimates.” Advances in wound care vol. 8,2 (2019): 39-88. doi:10.1089/wound.2019.0946 Armstrong, David G etal. “Complete wound closure following a single topical application of a novel autologous

  33. Slide 33: References (Continued)

    References (Continued) @ reese hee Sefer 20. 35. 36. 37. 38, Bates-Jensen BM, Guihan M, Garber SL, Chin AS, Burns SP. Characteristics of recurrent pressure ulcers in veterans with spinal cord injury. J Spinal Cord Med. 2009;32(1)'34-42. <doi:10.1080/10790268.2009 11760750 Padula, W. V., & Delarmente

PolarityTE — Investor Presentation (July 2021) on 6ix